ISRCTN15089342进行中（未招募）Unknown
Medication brand changes in hormone therapy for breast cancer. A community pharmacy intervention development to improve patients’ adherence and quality of life
ondon Metropolitan University0 个研究点目标入组 45 人开始时间: 2024年6月25日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •WP1 - 1.c Qualitative interviews with pharmacists:
- •1.Pharmacists who are owner or manager of a community pharmacy, chain and independent;
- •2.pharmacists with a representative role in professional pharmaceutical bodies, e.g. Local Pharmaceutical Committee, Community Pharmacy England, Royal Pharmaceutical Society.
- •WP2 - 2b. Qualitative interviews with pharmacists:
- •1.A pharmacist or pharmacist technician, permanent or locum (and)
- •2.Working in community pharmacies located in London (and)
- •3.Providing hormone therapy medication to clients
- •WP3 – Testing and optimisation studies
- •Pharmacists:
- •1.Pharmacists and pharmacy technicians; from the London boroughs of Barnet, Camden, Enfield, Haringey, or Islington
- •2.Providing Hormone Therapy medication to clients
- •3.Agree to participate in online training
- •4.Agree to recruit 4 patients from their pharmacy
- •5.Agree to deliver a medication consultation with recruited participants and audio record 1 consultation (with patient consent), and provide feedback notes of the consultation.
- •6.Agree to provide feedback in a study follow-up interview.
- •7.Is willing to provide written (signed and dated) informed consent.
- •1.Women 18+ with early BC (stage 1-3);
- •2.Talking oral HT medication (tamoxifen, anastrozole, or letrozole) and had/have concerns about changing HT brands;
- •3.Not taking HT medication as neo-adjuvant or secondary metastatic BC;
- •4.Is willing and able to record notes on side effects and medication taken (diary) and attend a medication consultation with the CP;
- •5.Is willing and able to participate in a study follow-up interview (phone or video conference);
- •6.Is willing to provide a copy of the diary;
- •7.Is willing to be audio recorded during the pharmacy consultation;
- •8.Is willing to provide written (signed and dated) informed consent.
排除标准
- •WP1 - 1.c Qualitative interviews with pharmacists:
- •1.locum, technician, assistants, pharmacist not owner or manager
- •2.Pharmacists without a representative role in professional pharmaceutical bodies
- •WP2 - 2b. Qualitative interviews with pharmacists:
- •1.Accredited Checking Technician, assistants
- •WP3 – Testing and optimisation studies
- •Pharmacists:
- •1.Locum, Accredited Checking Technician, pharmacy assistants.
- •2.Currently or recently (last 6 months) involved in another research study where medication adherence is a primary outcome;
- •3.Have had in the last 6 months a medication review about changing brands of HT drugs.
研究者
相似试验
已完成
3 期
Comparative effects of 2 types of hormone replacement therapy on climacteric symptomsmenopause.Menopausal and female climacteric statesIRCT138809032766N1Tarbiat Maodares University150
已完成
不适用
ational randomised trial of hormone replacement therapy (HRT) in women with a history of early stage breast cancerBreastCancerISRCTN29941643Individual Sponsor (UK)3,000
进行中（未招募）
不适用
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapyFemale patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapyMedDRA version: 14.1Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-000155-16-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
已完成
3 期
HABITSHormonal replacement therapy after breast cancer diagnosis - is it safe?Breast CancerACTRN12607000038493Regional Oncologic Centre, Sweden1,300
进行中（未招募）
不适用
Effect of hormone replacement therapy versus risedronate on fracture recurrence in postmenopausal women with hip fractureEndocrine, nutritional and metabolic diseaseKCT0005513Samsung Medical Center300